Technologies
This technology employs a unique combination of synthetic silicate nanoplatelets and heparin to form a shear-thinning hydrogel by simple mixing within one minute. The nanoplatelets create a “house-of-cards” structure through electrostatic face-to-edge interactions while heparin establishes reversible non-covalent crosslinks that stabilize therapeutic proteins. Adjustable gelation is achieved by tuning the heparin-to-nanoplatelet ratio and overall solid concentration, enabling controlled and sustained release of proteins such as FGF2. Its favorable rheological properties support easy injection and complete biodegradation in vivo within eight weeks, with minimal inflammation.